None listed
Conditions
Interventions
Intervention1: Test Product: Glutathione Tablets: Test Product: Glutathione Tablets Dose: BD(Two times a day)
Route of Administration: Oral
Duration: 12 Weeks
Control Intervention1: Not Applicable: No
Sponsors
Health Q lifesciences Pvt. Ltd.
Eligibility
Inclusion criteria
Inclusion criteria: 1)Gender: Male or Female with age 18-45 2)Subject having and dull skin. 3)Subjects willing to give written informed consent 4)Women of child bearing potential must have a negative urine pregnancy test prior to study entry. 5)Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events. 6.Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study.
Exclusion criteria
Exclusion criteria: 1.Subjects who are pregnant, breast-feeding, or planning to become pregnant during the study. 2.Have any evidence of systemic cancer, squamous cell carcinoma, basal cell carcinoma, in the last 5 years, or any other confounding skin condition. 3.Have open sores or open lesions in the treatment area(s). 4.Have any condition that, in the opinion of the investigator, would confound the safety and/or efficacy assessments of the product. 5.Have participated in any interventional clinical trial in the previous 90 days. 6.Have a known sensitivity to any of the constituents of the test product including sensitivities to (mention some of active ingredient s name) 7.Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication (i.e., biologics), including corticosteroids. 8.Have not skin related issues.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Change in Gloss 2. Change in Hydration 3. Change in Pigmentation 4. Change in Wrinkles 5. Dermat Evaluation (smoothness, skin even tone, Skin Texture)Timepoint: At Day 0, Week 2, Week 4, Week 8, and Week 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Visio-Scan ImagingTimepoint: At Day 0, Week 4, Week 8, and Week 12;1.Complete Blood CountTimepoint: At Day0, Week 4, and Week 12 | — |
Countries
India
Contacts
Public ContactPuneet Mittal
CCFT Laboratories
Outcome results
None listed